Evidence map›Paper›PMID 33033585›Full record

ArticleComputational and structural biotechnology journal2020

Identification of key genes and important histone modifications in hepatocellular carcinoma.

Yu-Xian Liu, Qian-Zhong Li, Yan-Ni Cao, Lu-Qiang Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models.Canadian journal of gastroenterology & hepatology · 2021
    Review
  20. Frontiers in veterinary science · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yu-Xian LiuLaboratory of Theoretical Biophysics, School of Physical Science and Technology, Inner Mongolia University, Hohhot 010021, China.
Qian-Zhong LiLaboratory of Theoretical Biophysics, School of Physical Science and Technology, Inner Mongolia University, Hohhot 010021, China.
Yan-Ni CaoLaboratory of Theoretical Biophysics, School of Physical Science and Technology, Inner Mongolia University, Hohhot 010021, China.
Lu-Qiang ZhangLaboratory of Theoretical Biophysics, School of Physical Science and Technology, Inner Mongolia University, Hohhot 010021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in the world. It has been reported that HCC is closely related to the changes of histone modifications. However, finding histone modification patterns in key genes which related to HCC is still an important task. In our study, the patterns of 11 kinds of histone modifications in the promoter regions for the different types of genes were analyzed by hierarchical screening for hepatocyte (normal) cell line and HepG2 (tumor) cell line. The important histone modifications and their key modification regions in different types of genes were found. The results indicate that these important genes may play a pivotal role in the occurrence of HCC. By analyzing the differences of histone modifications and gene expression levels for these important genes between the two cell lines, we found that the signals of H3K4me3, H3K27ac, H3K9ac, and H3K4me2 in HCC are significantly stronger. The changed regions of important histone modifications in 17 key genes were also identified. For example, the H3K4me3 signals increased 150 times in regions (-1500, -500) bp and (0, 1000) bp of

Indexed as

BiomarkersDHLEG, Different highly and lowly expressed genesGene expressionH2AFZ, H2A histone family member ZH3K27ac, Histone H3 acetylated at lysine 27H3K27me3, Histone H3 trimethylated at lysine 27H3K36me3, Histone H3 trimethylated at lysine 36H3K4me1, Histone H3 monomethylated at lysine 4H3K4me2, Histone H3 dimethylated at lysine 4H3K4me3, Histone H3 trimethylated at lysine 4H3K79me2, Histone H3 dimethylated at lysine 79H3K9ac, Histone H3 acetylated at lysine 9H3K9me3, Histone H3 trimethylated at lysine 9H4K20me1, Histone H4 monomethylated at lysine 20HCC, Hepatocellular carcinomaHistone modification signalsNH, The genes are highly expressed in normal cell line but not in tumor cell lineNH-TL, The genes are highly expressed in normal cell line and lowly expressed in tumor cell lineNL, The genes are lowly expressed in normal cell line but not in tumor cell lineNL-TH, The genes are lowly expressed in normal cell line and highly expressed in tumor cell lineOncogenesONCO, OncogenesTH, The genes are highly expressed in tumor cell line but not in normal cell lineTL, The genes are lowly expressed in tumor cell line but not in normal cell lineTSG, Tumor suppressor genesTumor suppressor genes

Identifiers

PMID33033585
PMCPMC7533298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.